4Front Ventures (4Front Ventures) Debt-to-Asset : 0.80 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is 4Front Ventures Debt-to-Asset?

4Front Ventures's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $27.4 Mil. 4Front Ventures's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $182.5 Mil. 4Front Ventures's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $264.0 Mil. 4Front Ventures's debt to asset for the quarter that ended in Dec. 2023 was 0.79.

4Front Ventures Debt-to-Asset Historical Data

The historical data trend for 4Front Ventures's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4Front Ventures Debt-to-Asset Chart

4Front Ventures Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.23

0.59

0.66

0.60

0.80

4Front Ventures Quarterly Data
	Jan19	Apr19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.60	0.67	0.68	0.77	0.80

Competitive Comparison of 4Front Ventures's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4Front Ventures's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's Debt-to-Asset falls into.

4Front Ventures Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

4Front Ventures's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(27.35	+	182.489)	/	263.954
	=	0.79

4Front Ventures's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(27.35	+	182.489)	/	263.954
	=	0.79

4Front Ventures (OTCPK:FFNTF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

4Front Ventures Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of 4Front Ventures's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

4Front Ventures (4Front Ventures) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » 4Front Ventures Corp (OTCPK:FFNTF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

FFNT:Canada

Address

5060 North 40th Street, Suite 120, Phoenix, AZ, USA, 85018

Website

https://www.4frontventures.com

4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.

Executives

Leonid Gontmakher	director, officer: Chief Executive Officer	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Nicole Frederick	officer: See Remarks	C/O 4FRONT VENTURES CORP., 7010 E. CHAUNCEY LANE STE. 235, PHOENIX AZ 85054
Kristopher Krane	director	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
David Ryan Daily	director	5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Roman Tkachenko	director	5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Karl Chowscano	other: Consultant	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Chetan Gulati	director	28 REICHERT CIRCLE, WESTPORT CT 06880
Keith Edward Adams	officer: Chief Financial Officer	108 S. WETHERLY DRIVE, UNIT 4, LOS ANGELES CA 90048
Robert E Hunt	director	C/O GROWLIFE, INC., 20301 VENTURA BLVD., SUITE 126, WOODLAND HILLS CA 91364
Amit Ramanlal Patel	director	3305 PINE AVENUE, MANHATTAN BEACH CA 90266
Kathi P Lentzsch	director	5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Andrew Thut	officer: Chief Investment Officer	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Joseph R Feltham	officer: Chief Operating Officer	5060 N. 40TH STREET, STE 120, PHOENIX AZ 85018
Eric J. Rey	director	ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Nicolle Dorsey	officer: Chief Financial Officer	C/O REAL GOODS SOLAR, INC., 110 16TH STREET, 3RD FLOOR, DENVER CO 80202